Publication
Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (9)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 9
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- drugZongertinibcivic_curation1.00
- geneERBB2civic_curation1.00
- variantERBB2 A775_G776insYVMAcivic_curation1.00
- variantERBB2 G776delinsVCcivic_curation1.00
- variantERBB2 G776Vcivic_curation1.00
- variantERBB2 L755Pcivic_curation1.00
- variantERBB2 Mutationcivic_curation1.00
- variantERBB2 P780_Y781insGSPcivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 40293180
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ERBB2 A775_G776insYVMA1 | ||||||||
| Zongertinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID12564In the multicohort phase 1b Beamion LUNG-1 trial (NCT04886804) of zongertinib in HER2-mutant NSCLC, three cohorts were evaluated by mutation type and prior therapy. In cohort 1 (n = 75; HER2-TKD mutat… (full text at CIViC) PMID 40293180 · Heymach et al., 2025 · Open in CIViC | civic |
| ERBB2 G776delinsVC + ERBB2 G776V + ERBB2 L755P + ERBB2 P780_Y781insGSP1 | ||||||||
| Zongertinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID12563In the multicohort phase 1b Beamion LUNG-1 trial (NCT04886804) of zongertinib in HER2-mutant NSCLC, three cohorts were evaluated by mutation type and prior therapy. In cohort 1 (n = 75; HER2-TKD mutat… (full text at CIViC) PMID 40293180 · Heymach et al., 2025 · Open in CIViC | civic |
| ERBB2 Mutation1 | ||||||||
| Zongertinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID12530The authors report evaluation of zongertinib in a multicohort, phase 1a/1b trial involving patients with advanced or metastatic HER2-mutant non-small cell lung cancer. Three cohorts of patients are re… (full text at CIViC) PMID 40293180 · Heymach et al., 2025 · Open in CIViC | civic |